MD Anderson Cancer Center Acquires Two Elekta Versa HD Systems
HOUSTON, April 18 – The University of Texas MD Anderson Cancer Center (Houston, Texas) has purchased two Elekta Versa HD™ linear accelerators. The radiation therapy system, which recently received 510(k) clearance from the U.S. Food and Drug Administration, features the versatility to deliver high-volume conventional techniques, in addition to the most advanced linear-accelerator treatments that require the greatest targeting precision. MD Anderson predicts it will be ready to treat patients on the systems by January 2014.
Versa HD is equipped with the Agility™ multileaf collimator for high-speed, high-precision beam shaping to support extremely accurate tumor targeting and improved healthy tissue preservation. With previous beam shaping technologies, high-definition (HD) beam shaping was limited to small targets. Versa HD with Agility now enables high-definition beam shaping over a significantly larger treatment field, expanding advanced treatments to a broader spectrum of tumors. Combining this novel technology with a new High Dose Rate mode, Versa HD is expected to provide rapid delivery of more sophisticated therapies within standard radiotherapy treatment times.
“To have MD Anderson employ our latest technology gives us added confidence that Elekta is providing the tools that top healthcare providers need to treat their patients,” says Jay Hoey, Executive Vice President, Elekta North America.
Learn more at www.VersaHD.com.
Versa HD is not available for sale or distribution in all markets.
# # #
For further information, please contact:
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: email@example.com
Time zone: ET: Eastern Time
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on April 18, 2013.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.